13 July 2012
BDA advises on sale of SunTech Medical to Halma
divested medical supply business to
2012
Business Development Asia LLC (“BDA”) is pleased to announce that SunTech Medical Group Limited (“SunTech”), a pre-eminent supplier of clinical grade non-invasive blood pressure monitoring products and technologies, has been acquired by Halma plc (“Halma”), a U.K.-based developer of hazard and life protection products. BDA served as a joint financial advisor to SunTech in the transaction along with Greene Holcomb & Fisher (“GH&F”).
Following the transaction, SunTech management will remain in place and continue to operate the business. Dayne McBee, CEO of SunTech commented, “We are extremely pleased with the transaction outcome. We are excited to join the Halma team and continue to develop innovative blood pressure monitoring technologies.”
SunTech will join the Health Optics business within Halma’s Health and Analysis sector, which includes Riester, Keeler, Volk and Accutome. Andrew Williams, Halma’s Chief Executive, stated, “The acquisition of SunTech continues our strategy of building strong positions in markets with resilient long-term growth drivers. Their blood pressure monitoring technology is a perfect complement to Riester’s own clinical grade blood pressure monitoring devices and this acquisition allows the two companies to work together to further develop their markets and products.”
About SunTech Medical Group
SunTech is a pre-eminent supplier of clinical-grade, non-invasive blood pressure (“NIBP”) monitoring products and technologies, both directly under the SunTech brand name and indirectly through over 75 leading medical device OEMs. The company offers solutions for a range of NIBP applications, including in-clinic, out of office and cardiac stress test applications. SunTech has a strong history of product innovation and excellence. Further information is available on www.suntechmed.com
About Halma plc
Halma develops and markets products that are used to protect lives, or improve the quality of life, for individuals and businesses worldwide. It operates through three distinct business sectors: Health and Analysis, Infrastructure Sensors, and Industrial Safety. The Health and Analysis sector manufactures components and products used to improve personal and public health. Within this sector, SunTech will join the Health Optics sub-sector, which manufactures handheld devices used to assess eye health, diagnose disease and assist with eye surgery as well as diagnostic devices for general medical applications. Further information is available on www.halma.com
About Business Development Asia
Business Development Asia LLC (“BDA”) assists multinational corporate and financial sector clients to identify and execute acquisitions, divestments, JVs, restructuring and capital raising, in Asia and internationally. The company is headquartered in New York with offices in London, Bahrain, Mumbai, Hong Kong, Beijing, Shanghai, Seoul, and Tokyo. BDA employs 70 full-time professional staff across its nine offices, supplemented by a team of senior advisors around the world. BDA’s clients include Areva, AXA Private Equity, Celestica, Clariant, Dai Nippon Ink and Chemicals, Ecolab, GSK, Hanjin, Henkel, Hercules, Kennametal, Materion, Molex, Nalco, Nova Capital Partners, Pfizer, Rexel, Ryder, Sun Chemical, TATA Group, ThomsonReuters, Weir, and WestLB. Further information on BDA is available at www.bdapartners.com
For more information regarding this transaction, please contact Euan Rellie on 212 265 5300 or erellie@bdallc.com
Recent transactions
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019